Skip to main contentSkip to navigationSkip to search
ENZY  
SEK  %
Logotype

Investors

The share

Volume, thousands
[{"d":"2022-11-16","n":"Enzymatica and University of Kent launch study to explore prevention of upper respiratory virus infections in elite athletes","u":"/media/press-releases/2022/enzymatica-and-university-of-kent-launch-study-to-explore-prevention-of-upper-respiratory-virus-infections-in-elite-athletes/"},{"d":"2022-11-02","n":"Interim report Q3/2022: A broader role for ColdZyme adds potential for the future","u":"/media/press-releases/2022/interim-report-q32022-a-broader-role-for-coldzyme-adds-potential-for-the-future/"},{"d":"2022-11-01","n":"New study confirms ColdZyme stops viruses causing Covid-19 from adhering to human respiratory cells","u":"/media/press-releases/2022/new-study-confirms-coldzyme-stops-viruses-causing-covid-19-from-adhering-to-human-respiratory-cells/"},{"d":"2022-08-26","n":"Enzymatica announces outcome of new rights issue","u":"/media/press-releases/2022/enzymatica-announces-outcome-of-new-rights-issue/"},{"d":"2022-08-18","n":"Enzymatica publishes supplementary prospectus","u":"/media/press-releases/2022/enzymatica-publishes-supplementary-prospectus/"},{"d":"2022-08-16","n":"ColdZyme also blocks omicron variants BA.4 and BA.5","u":"/media/press-releases/2022/coldzyme-also-blocks-omicron-variants-ba4-and-ba5/"},{"d":"2022-08-05","n":"Publication of prospectus regarding Enzymatica’s rights issue","u":"/media/press-releases/2022/publication-of-prospectus-regarding-enzymaticas-rights-issue/"},{"d":"2022-07-19","n":"Interim report Q2/2022: Improved sales give confidence for the future","u":"/media/press-releases/2022/interim-report-q22022-improved-sales-give-confidence-for-the-future/"},{"d":"2022-07-19","n":"Enzymatica’s Board of Directors decides on a new rights issue of SEK 74.7 million","u":"/media/press-releases/2022/enzymaticas-board-of-directors-decides-on-a-new-rights-issue-of-sek-747-million/"},{"d":"2022-06-23","n":"ColdZyme blocks omicron virus – according to new research","u":"/media/press-releases/2022/coldzyme-blocks-omicron-virus--according-to-new-research/"},{"d":"2022-06-16","n":"Enzymatica signs loan agreement with major shareholders","u":"/media/press-releases/2022/enzymatica-signs-loan-agreement-with-major-shareholders/"},{"d":"2022-04-28","n":"Bulletin from Annual General Meeting of Enzymatica AB (publ) on 28 April 2022","u":"/media/press-releases/2022/bulletin-from-annual-general-meeting-of-enzymatica-ab-publ-on-28-april-2022/"},{"d":"2022-04-28","n":"Interim report Q1/2022: Our financial targets remain in place","u":"/media/press-releases/2022/interim-report-q12022-our-financial-targets-remain-in-place/"},{"d":"2022-04-11","n":"Article about ColdZyme acquitted from suspicions of research misconduct","u":"/media/press-releases/2022/article-about-coldzyme-acquitted-from-suspicions-of-research-misconduct/"},{"d":"2022-04-04","n":"Enzymatica’s mouth spray to be launched in Turkey","u":"/media/press-releases/2022/enzymaticas-mouth-spray-to-be-launched-in-turkey/"},{"d":"2022-03-31","n":"Enzymatica publishes annual report for 2021","u":"/media/press-releases/2022/enzymatica-publishes-annual-report-for-2021/"},{"d":"2022-03-28","n":"Notice of Annual General Meeting 2022 in Enzymatica AB (publ)","u":"/media/press-releases/2022/notice-of-annual-general-meeting-2022-in-enzymatica-ab-publ/"},{"d":"2022-03-03","n":"Enzymatica’s mouth spray to be launched in Mexico","u":"/media/press-releases/2022/enzymaticas-mouth-spray-to-be-launched-in-mexico/"},{"d":"2022-02-17","n":"Year-end report: Clear signs of favourable market trends after a challenging 2021","u":"/media/press-releases/2022/year-end-report-clear-signs-of-favourable-market-trends-after-a-challenging-2021/"},{"d":"2022-01-12","n":"Enzymatica comments on wrongful wording in Dagens Medicin","u":"/media/press-releases/2022/enzymatica-comments-on-wrongful-wording-in-dagens-medicin/"},{"d":"2021-11-02","n":"The long-term plan remains in challenging times","u":"/media/press-releases/2021/the-long-term-plan-remains-in-challenging-times/"},{"d":"2021-11-02","n":"Enzymatica Board decides on financial targets","u":"/media/press-releases/2021/enzymatica-board-decides-on-financial-targets/"},{"d":"2021-10-18","n":"Bulletin from the extraordinary general meeting in Enzymatica AB (publ)","u":"/media/press-releases/2021/bulletin-from-the-extraordinary-general-meeting-in-enzymatica-ab-publ/"},{"d":"2021-09-29","n":"Notice of extraordinary general meeting in Enzymatica AB (publ)","u":"/media/press-releases/2021/notice-of-extraordinary-general-meeting-in-enzymatica-ab-publ/"},{"d":"2021-09-08","n":"Claus Egstrand takes office as CEO ahead of schedule","u":"/media/press-releases/2021/claus-egstrand-takes-office-as-ceo-ahead-of-schedule/"},{"d":"2021-08-11","n":"Chinese and US patent authorities issue notices of allowance for patent for key component in cold spray ColdZyme","u":"/media/press-releases/2021/chinese-and-us-patent-authorities-issue-notices-of-allowance-for-patent-for-key-component-in-cold-spray-coldzyme/"},{"d":"2021-07-16","n":"Continued lower sales due to pandemic but some stabilization","u":"/media/press-releases/2021/continued-lower-sales-due-to-pandemic-but-some-stabilization/"},{"d":"2021-07-13","n":"Claus Egstrand appointed new CEO of Enzymatica","u":"/media/press-releases/2021/claus-egstrand-appointed-new-ceo-of-enzymatica/"},{"d":"2021-07-12","n":"Enzymatica and STADA extend agreement on ViruProtect to Vietnam","u":"/media/press-releases/2021/enzymatica-and-stada-extend-agreement-on-viruprotect-to-vietnam/"},{"d":"2021-06-22","n":"Enzymatica appoints new Director of Quality Assurance and Communication Manager","u":"/media/press-releases/2021/enzymatica-appoints-new-director-of-quality-assurance-and-communication-manager/"},{"d":"2021-06-07","n":"Enzymatica announces outcome of new rights issue","u":"/media/press-releases/2021/enzymatica-announces-outcome-of-new-rights-issue/"},{"d":"2021-06-03","n":"Enzymatica launches ColdZyme on Amazon","u":"/media/press-releases/2021/enzymatica-launches-coldzyme-on-amazon/"},{"d":"2021-05-21","n":"Patent for ColdZyme approved in Japan","u":"/media/press-releases/2021/patent-for-coldzyme-approved-in-japan/"},{"d":"2021-05-12","n":"Prospectus for Enzymatica’s rights issue is published","u":"/media/press-releases/2021/prospectus-for-enzymaticas-rights-issue-is-published/"},{"d":"2021-05-05","n":"Bulletin from Annual General Meeting of Enzymatica AB (publ) on 5 May 2021","u":"/media/press-releases/2021/bulletin-from-annual-general-meeting-of-enzymatica-ab-publ-on-5-may-2021/"},{"d":"2021-04-29","n":"Lower sales due to the pandemic but new rights issue secures continued international expansion","u":"/media/press-releases/2021/lower-sales-due-to-the-pandemic-but-new-rights-issue-secures-continued-international-expansion/"},{"d":"2021-03-31","n":"Enzymatica Publication of the Annual Report 2020","u":"/media/press-releases/2021/enzymatica-publication-of-the-annual-report-2020/"},{"d":"2021-03-31","n":"Notice of Annual General Meeting 2021 in Enzymatica AB (publ)","u":"/media/press-releases/2021/notice-of-annual-general-meeting-2021-in-enzymatica-ab-publ/"},{"d":"2021-03-29","n":"Enzymatica’s Board of Directors decides on a new rights issue of SEK 59.1 million","u":"/media/press-releases/2021/enzymaticas-board-of-directors-decides-on-a-new-rights-issue-of-sek-591-million/"},{"d":"2021-03-22","n":"Enzymatica’s sales and result affected by the pandemic","u":"/media/press-releases/2021/enzymaticas-sales-and-result-affected-by-the-pandemic/"},{"d":"2021-02-18","n":"Positive operating result and almost doubled sales for the fourth quarter","u":"/media/press-releases/2021/positive-operating-result-and-almost-doubled-sales-for-the-fourth-quarter/"},{"d":"2021-02-11","n":"Enzymatica comments on article in Dagens Medicin","u":"/media/press-releases/2021/enzymatica-comments-on-article-in-dagens-medicin/"},{"d":"2021-01-15","n":"New strategic recruitments and organizational changes at Enzymatica","u":"/media/press-releases/2021/new-strategic-recruitments-and-organizational-changes-at-enzymatica/"},{"d":"2020-12-09","n":"STADA agreement extended for the Nordic Region","u":"/media/press-releases/2020/stada-agreement-extended-for-the-nordic-region/"},{"d":"2020-11-12","n":"Enzymatica enters agreement with MS Pharma for MENA","u":"/media/press-releases/2020/enzymatica-enters-agreement-with-ms-pharma-for-mena/"},{"d":"2020-11-03","n":"Continued strong sales increase and positive cash flow in third quarter","u":"/media/press-releases/2020/continued-strong-sales-increase-and-positive-cash-flow-in-third-quarter/"},{"d":"2020-10-21","n":"Enzymatica enters agreement with Sanofi for covering France and Italy on common cold spray Coldzyme®","u":"/media/press-releases/2020/enzymatica-enters-agreement-with-sanofi-for-covering-france-and-italy-on-common-cold-spray-coldzyme/"},{"d":"2020-10-13","n":"Enzymatica and STADA extend agreement on ViruProtect to Russia, Poland, Ukraine and CIS countries","u":"/media/press-releases/2020/enzymatica-and-stada-extend-agreement-on-viruprotect-to-russia-poland-ukraine-and-cis-countries/"},{"d":"2020-10-07","n":"ColdZyme launched in Israel","u":"/media/press-releases/2020/coldzyme-launched-in-israel/"},{"d":"2020-09-28","n":"The Journal of Medical Virology has peer reviewed, approved and published the results of Enzymatica’s in vitro study on SARS-CoV-2","u":"/media/press-releases/2020/the-journal-of-medical-virology-has-peer-reviewed-approved-and-published-the-results-of-enzymaticas-in-vitro-study-on-sars-cov-2/"},{"d":"2020-09-23","n":"New patents approved for ColdZyme in Japan and Russia","u":"/media/press-releases/2020/new-patents-approved-for-coldzyme-in-japan-and-russia/"},{"d":"2020-09-17","n":"New version – corrected 17 September, 2020 The results of Enzymatica's placebo-controlled, randomized study","u":"/media/press-releases/2020/new-version--corrected-17-september-2020-the-results-of-enzymaticas-placebo-controlled-randomized-study/"},{"d":"2020-08-17","n":"The results of Enzymatica's placebo-controlled, randomized study show statistically significant shorter common colds and good treatment efficacy when using ColdZyme","u":"/media/press-releases/2020/the-results-of-enzymaticas-placebo-controlled-randomized-study-show-statistically-significant-shorter-common-colds-and-good-treatment-efficacy-when-using-coldzyme/"},{"d":"2020-07-20","n":"A new in vitro study shows the ability of ColdZyme to deactivate SARS-CoV-2, the cause of the COVID-19 pandemic","u":"/media/press-releases/2020/a-new-in-vitro-study-shows-the-ability-of-coldzyme-to-deactivate-sars-cov-2-the-cause-of-the-covid-19-pandemic/"},{"d":"2020-07-16","n":"Doubled sales also during the second quarter","u":"/media/press-releases/2020/doubled-sales-also-during-the-second-quarter/"},{"d":"2020-06-03","n":"Shorter duration of common colds for endurance athletes with ColdZyme","u":"/media/press-releases/2020/shorter-duration-of-common-colds-for-endurance-athletes-with-coldzyme/"},{"d":"2020-05-25","n":"Enzymatica and STADA extend agreement for Europe","u":"/media/press-releases/2020/enzymatica-and-stada-extend-agreement-for-europe/"},{"d":"2020-05-19","n":"Grant of European patent for ColdZyme","u":"/media/press-releases/2020/grant-of-european-patent-for-coldzyme/"},{"d":"2020-05-18","n":"Changes in management at Enzymatica","u":"/media/press-releases/2020/changes-in-management-at-enzymatica/"},{"d":"2020-05-05","n":"Bulletin from Annual General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2020/bulletin-from-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2020-05-05","n":"Doubled sales and positive earnings for the first quarter","u":"/media/press-releases/2020/doubled-sales-and-positive-earnings-for-the-first-quarter/"},{"d":"2020-04-24","n":"ColdZyme re-certified to class III in the EU","u":"/media/press-releases/2020/coldzyme-re-certified-to-class-iii-in-the-eu/"},{"d":"2020-04-21","n":"Enzymatica enables postal voting at the Annual General Meeting 2020","u":"/media/press-releases/2020/enzymatica-enables-postal-voting-at-the-annual-general-meeting-2020/"},{"d":"2020-04-03","n":"Notice of annual general meeting 2020 in Enzymatica AB (publ)","u":"/media/press-releases/2020/notice-of-annual-general-meeting-2020-in-enzymatica-ab-publ/"},{"d":"2020-04-02","n":"Enzymatica - publication of the Annual Report 2019","u":"/media/press-releases/2020/enzymatica---publication-of-the-annual-report-2019/"},{"d":"2020-03-27","n":"Enzymatica gets increased sales due to the Corona situation","u":"/media/press-releases/2020/enzymatica-gets-increased-sales-due-to-the-corona-situation/"},{"d":"2020-03-20","n":"Enzymatica signs agreement with Chemipal for Israel","u":"/media/press-releases/2020/enzymatica-signs-agreement-with-chemipal-for-israel/"},{"d":"2020-03-03","n":"Strong results from preventive use of ColdZyme against common cold virus","u":"/media/press-releases/2020/strong-results-from-preventive-use-of-coldzyme-against-common-cold-virus/"},{"d":"2020-02-13","n":"ColdZyme – third largest cold brand in Sweden","u":"/media/press-releases/2020/coldzyme--third-largest-cold-brand-in-sweden/"},{"d":"2020-02-12","n":"Shorter colds and milder symptoms among children who use ColdZyme","u":"/media/press-releases/2020/shorter-colds-and-milder-symptoms-among-children-who-use-coldzyme/"},{"d":"2020-02-03","n":"The European Patent Office recommends grant of a new patent covering a key ingredient in ColdZyme against the common cold","u":"/media/press-releases/2020/the-european-patent-office-recommends-grant-of-a-new-patent-covering-a-key-ingredient-in-coldzyme-against-the-common-cold/"},{"d":"2020-01-28","n":"The Nomination Committee proposes that Fredrik Lindberg is elected to the Board of Directors","u":"/media/press-releases/2020/the-nomination-committee-proposes-that-fredrik-lindberg-is-elected-to-the-board-of-directors/"},{"d":"2020-01-22","n":"Enzymatica signs agreement with Keyuan Trade for China","u":"/media/press-releases/2020/enzymatica-signs-agreement-with-keyuan-trade-for-china/"},{"d":"2020-01-14","n":"ColdZyme launched in Hong Kong","u":"/media/press-releases/2020/coldzyme-launched-in-hong-kong/"},{"d":"2019-12-21","n":"Enzymatica’s CEO resigns","u":"/media/press-releases/2019/enzymaticas-ceo-resigns/"},{"d":"2019-12-13","n":"Enzymatica in agreement for enzyme formulations for the Chinese skin care market","u":"/media/press-releases/2019/enzymatica-in-agreement-for-enzyme-formulations-for-the-chinese-skin-care-market/"},{"d":"2019-11-28","n":"STADA collaboration expands in Germany","u":"/media/press-releases/2019/stada-collaboration-expands-in-germany/"},{"d":"2019-11-05","n":"Very strong increase of sales during the third quarter","u":"/media/press-releases/2019/very-strong-increase-of-sales-during-the-third-quarter/"},{"d":"2019-10-10","n":"Enzymatica recruits new Director of Quality Assurance","u":"/media/press-releases/2019/enzymatica-recruits-new-director-of-quality-assurance/"},{"d":"2019-09-04","n":"Preliminary results of Enzymatica’s placebo-controlled, randomized study did not meet the primary end-point","u":"/media/press-releases/2019/preliminary-results-of-enzymaticas-placebo-controlled-randomized-study-did-not-meet-the-primary-end-point/"},{"d":"2019-08-26","n":"ColdZyme launches with new flavor and new product claims","u":"/media/press-releases/2019/coldzyme-launches-with-new-flavor-and-new-product-claims/"},{"d":"2019-07-17","n":"Good growth in Q2, driven mainly by strong sales in Sweden","u":"/media/press-releases/2019/good-growth-in-q2-driven-mainly-by-strong-sales-in-sweden/"},{"d":"2019-06-19","n":"Enzymatica signs supply agreement with German cosmetic company Maren, amounting to a value of SEK 120 million over a period of three years","u":"/media/press-releases/2019/enzymatica-signs-supply-agreement-with-german-cosmetic-company-maren-amounting-to-a-value-of-sek-120-million-over-a-period-of-three-years/"},{"d":"2019-05-07","n":"Bulletin from Annual General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2019/bulletin-from-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2019-05-07","n":"Continued strong growth in Sweden, but lower total sales during the quarter","u":"/media/press-releases/2019/continued-strong-growth-in-sweden-but-lower-total-sales-during-the-quarter/"},{"d":"2019-05-03","n":"All patients enrolled in Enzymatica’s German placebo-controlled multicentre study with ColdZyme","u":"/media/press-releases/2019/all-patients-enrolled-in-enzymaticas-german-placebo-controlled-multicentre-study-with-coldzyme/"},{"d":"2019-04-16","n":"Enzymatica’s cold spray launched in South Africa","u":"/media/press-releases/2019/enzymaticas-cold-spray-launched-in-south-africa/"},{"d":"2019-02-19","n":"Enzymatica AB: Strong sales in the fourth quarter, but lower sales for full-year 2018 driven by restrictions in Germany","u":"/media/press-releases/2019/enzymatica-ab-strong-sales-in-the-fourth-quarter-but-lower-sales-for-full-year-2018-driven-by-restrictions-in-germany/"},{"d":"2019-01-30","n":"Enzymatica AB: First patients included in large placebo-controlled multicentre study on ColdZyme","u":"/media/press-releases/2019/enzymatica-ab-first-patients-included-in-large-placebo-controlled-multicentre-study-on-coldzyme/"},{"d":"2019-01-25","n":"Multi-symptom Relief and Improvement of Quality of Life - A Comparative Multicenter Trial on ColdZyme® Mouth Spray in Common Cold","u":"/media/press-releases/2019/multi-symptom-relief-and-improvement-of-quality-of-life---a-comparative-multicenter-trial-on-coldzyme-mouth-spray-in-common-cold/"},{"d":"2019-01-25","n":"Enzymatica AB: Results from German multicentre study strengthen and broaden ColdZyme's product claims","u":"/media/press-releases/2019/enzymatica-ab-results-from-german-multicentre-study-strengthen-and-broaden-coldzymes-product-claims/"},{"d":"2018-12-10","n":"Enzymatica AB: Appeal on Enzymatica's cold spray in Germany overruled","u":"/media/press-releases/2018/enzymatica-ab-appeal-on-enzymaticas-cold-spray-in-germany-overruled/"},{"d":"2018-12-02","n":"Enzymatica AB: Enzymatica raises SEK 98.7 million in completed share issue","u":"/media/press-releases/2018/enzymatica-ab-enzymatica-raises-sek-987-million-in-completed-share-issue/"},{"d":"2018-11-23","n":"Enzymatica signs another agreement in Asia with Evergreen for Hong Kong and Macau","u":"/media/press-releases/2018/enzymatica-signs-another-agreement-in-asia-with-evergreen-for-hong-kong-and-macau/"},{"d":"2018-11-12","n":"Enzymatica AB: Prospectus for Enzymatica's rights issue with preferential rights for existing shareholders published","u":"/media/press-releases/2018/enzymatica-ab-prospectus-for-enzymaticas-rights-issue-with-preferential-rights-for-existing-shareholders-published/"},{"d":"2018-11-05","n":"Enzymatica AB: Bulletin from Extraordinary General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2018/enzymatica-ab-bulletin-from-extraordinary-general-meeting-in-enzymatica-ab-publ/"},{"d":"2018-11-02","n":"Enzymatica AB: Enzymatica's rights issue is secured up to 100 percent","u":"/media/press-releases/2018/enzymatica-ab-enzymaticas-rights-issue-is-secured-up-to-100-percent/"},{"d":"2018-11-01","n":"New British study of endurance athletes shows reduced duration of colds with ColdZyme","u":"/media/press-releases/2018/new-british-study-of-endurance-athletes-shows-reduced-duration-of-colds-with-coldzyme/"},{"d":"2018-10-31","n":"Enzymatica AB: Breakthrough agreement for Japan and lower sales in Q3 due to restrictions in Germany","u":"/media/press-releases/2018/enzymatica-ab-breakthrough-agreement-for-japan-and-lower-sales-in-q3-due-to-restrictions-in-germany/"},{"d":"2018-10-18","n":"Enzymatica AB: Notice of Extraordinary General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2018/enzymatica-ab-notice-of-extraordinary-general-meeting-in-enzymatica-ab-publ/"},{"d":"2018-10-18","n":"Enzymatica AB: The Board of Directors of Enzymatica AB decides on rights issue of SEK 98.7 million","u":"/media/press-releases/2018/enzymatica-ab-the-board-of-directors-of-enzymatica-ab-decides-on-rights-issue-of--sek-987-million/"},{"d":"2018-10-18","n":"Enzymatica AB: Enzymatica signs agreement for the Japanese market","u":"/media/press-releases/2018/enzymatica-ab-enzymatica-signs-agreement-for-the-japanese-market/"},{"d":"2018-10-01","n":"Enzymatica AB: Significant benefits from ColdZyme in a major German multicenter study evaluating different common cold symptom scales","u":"/media/press-releases/2018/enzymatica-ab-significant-benefits-from-coldzyme-in-a-major-german-multicenter-study-evaluating-different-common-cold-symptom-scales/"},{"d":"2018-08-29","n":"Enzymatica AB: Appeal of court ruling on Enzymatica's cold spray in Germany","u":"/media/press-releases/2018/enzymatica-ab-appeal-of-court-ruling-on-enzymaticas-cold-spray-in-germany/"},{"d":"2018-07-31","n":"Enzymatica AB: Enzymatica signs agreement for ColdZyme with ABEX Pharmaceutica (Pty) Ltd for South Africa","u":"/media/press-releases/2018/enzymatica-ab-enzymatica-signs-agreement-for-coldzyme-with-abex-pharmaceutica-pty-ltd-for-south-africa/"},{"d":"2018-07-17","n":"Enzymatica AB: Lower sales in Q2 but 31% increase for the first half of the year","u":"/media/press-releases/2018/enzymatica-ab-lower-sales-in-q2-but-31-increase-for-the-first-half-of-the-year/"},{"d":"2018-07-16","n":"Enzymatica AB: Court ruling put restrictions on marketing of Enzymatica's cold spray in Germany","u":"/media/press-releases/2018/enzymatica-ab-court-ruling-put-restrictions-on-marketing-of-enzymaticas-cold-spray-in-germany/"},{"d":"2018-06-07","n":"Enzymatica AB: Enzymatica secures funding for operations","u":"/media/press-releases/2018/enzymatica-ab-enzymatica-secures-funding-for-operations/"},{"d":"2018-05-22","n":"Enzymatica AB: Enzymatica signs agreement with Qualia Pharma for Greece and Cyprus","u":"/media/press-releases/2018/enzymatica-ab-enzymatica-signs-agreement-with-qualia-pharma-for-greece-and-cyprus/"},{"d":"2018-04-26","n":"Enzymatica AB: Bulletin from annual general meeting 2018 in Enzymatica AB (publ)","u":"/media/press-releases/2018/enzymatica-ab-bulletin-from-annual-general-meeting-2018-in-enzymatica-ab-publ/"},{"d":"2018-04-26","n":"Enzymatica AB: Continued growth during the first quarter","u":"/media/press-releases/2018/enzymatica-ab-continued-growth-during-the-first-quarter/"},{"d":"2018-04-11","n":"Enzymatica AB: New results from Enzymatica's in vitro study: ColdZyme also deactivates corona virus","u":"/media/press-releases/2018/enzymatica-ab-new-results-from-enzymaticas-in-vitro-study-coldzyme-also-deactivates-corona-virus/"},{"d":"2018-04-11","n":"Stefansson et al, ColdZyme forms a protective barrier in the throat that deactivates five major common cold viruses, Congress of the Swedish Association of Otolaryngology, 2018_Abstract","u":"/media/press-releases/2018/stefansson-et-al-coldzyme-forms-a-protective-barrier-in-the-throat-that-deactivates-five-major-common-cold-viruses-congress-of-the-swedish-association-of-otolaryngology-2018_abstract/"},{"d":"2018-04-11","n":"Stefansson et al, ColdZyme forms a protective barrier in the throat that deactivates five major common cold viruses, Congress of the Swedish Association of Otolaryngology, 2018_Poster","u":"/media/press-releases/2018/stefansson-et-al-coldzyme-forms-a-protective-barrier-in-the-throat-that-deactivates-five-major-common-cold-viruses-congress-of-the-swedish-association-of-otolaryngology-2018_poster/"},{"d":"2018-04-09","n":"Enzymatica AB: New ColdZyme study in elite athletes confirms preventive effect and reduced duration of illness","u":"/media/press-releases/2018/enzymatica-ab-new-coldzyme-study-in-elite-athletes-confirms-preventive-effect-and-reduced-duration-of-illness/"},{"d":"2018-03-28","n":"Enzymatica AB: Enzymatica - publication of the annual report 2017","u":"/media/press-releases/2018/enzymatica-ab-enzymatica---publication-of-the-annual-report-2017/"},{"d":"2018-03-21","n":"Enzymatica AB: Notice of annual general meeting in Enzymatica AB (publ)","u":"/media/press-releases/2018/enzymatica-ab-notice-of-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2018-02-14","n":"Enzymatica AB: Strong growth and international breakthrough in 2017","u":"/media/press-releases/2018/enzymatica-ab-strong-growth-and-international-breakthrough-in-2017/"},{"d":"2017-12-27","n":"New customer survey – ColdZyme prevents colds and reduces severity and duration among cold sufferers","u":"/media/press-releases/2017/new-customer-survey--coldzyme-prevents-colds-and-reduces-severity-and-duration-among-cold-sufferers/"},{"d":"2017-11-29","n":"Enzymatica AB: Enzymatica's Nomination Committee for the Annual General Meeting 2018 appointed","u":"/media/press-releases/2017/enzymatica-ab-enzymaticas-nomination-committee-for-the-annual-general-meeting-2018-appointed/"},{"d":"2017-11-14","n":"Enzymatica AB: Enzymatica announces a study showing the ability of ColdZyme to deactivate major common cold viruses","u":"/media/press-releases/2017/enzymatica-ab-enzymatica-announces-a-study-showing-the-ability-of-coldzyme-to-deactivate-major-common-cold-viruses/"},{"d":"2017-11-09","n":"Enzymatica AB: ColdZyme study - Most recommended cold product at pharmacies","u":"/media/press-releases/2017/enzymatica-ab-coldzyme-study---most-recommended-cold-product-at-pharmacies/"},{"d":"2017-11-01","n":"Enzymatica AB: Interim report for Enzymatica AB (publ) January-September 2017","u":"/media/press-releases/2017/enzymatica-ab-interim-report-for-enzymatica-ab-publ-january-september-2017/"},{"d":"2017-10-25","n":"Enzymatica AB: Bulletin from extraordinary general meeting in Enzymatica AB (publ)","u":"/media/press-releases/2017/enzymatica-ab-bulletin-from-extraordinary-general-meeting-in-enzymatica-ab-publ/"},{"d":"2017-10-18","n":"Enzymatica AB: Complete article from COLDPREV I study published - strengthens documentation for ColdZyme","u":"/media/press-releases/2017/enzymatica-ab-complete-article-from-coldprev-i-study-published---strengthens-documentation-for-coldzyme/"},{"d":"2017-10-17","n":"Enzymatica AB: ColdZyme cold spray reduces sickness absence among preschool staff","u":"/media/press-releases/2017/enzymatica-ab-coldzyme-cold-spray-reduces-sickness-absence-among-preschool-staff/"},{"d":"2017-09-25","n":"Enzymatica AB: Notice of extraordinary general meeting regarding among other things personnel option program in Enzymatica AB (publ)","u":"/media/press-releases/2017/enzymatica-ab-notice-of-extraordinary-general-meeting-regarding-among-other-things-personnel-option-program-in-enzymatica-ab-publ/"},{"d":"2017-09-06","n":"Enzymatica recruits Chief Financial Officer","u":"/media/press-releases/2017/enzymatica-recruits-chief-financial-officer/"},{"d":"2017-07-20","n":"Enzymatica AB: Continued sales growth and breakthrough order from STADA","u":"/media/press-releases/2017/enzymatica-ab-continued-sales-growth-and-breakthrough-order-from-stada/"},{"d":"2017-07-18","n":"Enzymatica recruits Chief Commercial Officer","u":"/media/press-releases/2017/enzymatica-recruits-chief-commercial-officer/"},{"d":"2017-07-14","n":"Enzymatica recruits Chief Operating Officer","u":"/media/press-releases/2017/enzymatica-recruits-chief-operating-officer/"},{"d":"2017-06-21","n":"A study of elite athletes shows that ColdZyme provides protection as evidenced by fewer sick days and lost training days, as well as improved quality of life","u":"/media/press-releases/2017/a-study-of-elite-athletes-shows-that-coldzyme-provides-protection-as-evidenced-by-fewer-sick-days-and-lost-training-days-as-well-as-improved-quality-of-life/"},{"d":"2017-06-14","n":"Enzymatica receives record order from STADA Arzneimittel AG","u":"/media/press-releases/2017/enzymatica-receives-record-order-from-stada-arzneimittel-ag/"},{"d":"2017-05-23","n":"Bengt Jöndell continues as acting CFO","u":"/media/press-releases/2017/bengt-jondell-continues-as-acting-cfo/"},{"d":"2017-04-20","n":"Enzymatica AB: Bulletin from annual general meeting 2017 in Enzymatica AB (publ)","u":"/media/press-releases/2017/enzymatica-ab-bulletin-from-annual-general-meeting-2017-in-enzymatica-ab-publ/"},{"d":"2017-04-20","n":"Enzymatica AB: Breakthrough in Germany and continued increase in sales","u":"/media/press-releases/2017/enzymatica-ab-breakthrough-in-germany-and-continued-increase-in-sales/"},{"d":"2017-04-06","n":"Enzymatica AB: Enzymatica - publication of the annual report 2016","u":"/media/press-releases/2017/enzymatica-ab-enzymatica---publication-of-the-annual-report-2016/"},{"d":"2017-04-05","n":"Enzymatica AB: Completing the Nomination Committee's in Enzymatica AB proposal for AGM 2017 regarding election of auditor","u":"/media/press-releases/2017/enzymatica-ab-completing-the-nomination-committees-in-enzymatica-ab-proposal-for-agm-2017-regarding-election-of-auditor/"},{"d":"2017-03-21","n":"Enzymatica AB: Notice of annual general meeting in Enzymatica AB (publ)","u":"/media/press-releases/2017/enzymatica-ab-notice-of-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2017-02-16","n":"Enzymatica AB: Geographic expansion and continued growth in 2016","u":"/media/press-releases/2017/enzymatica-ab-geographic-expansion-and-continued-growth-in-2016/"},{"d":"2017-02-13","n":"Enzymatica AB: Enzymatica enters into partnership agreement with STADA Arzneimittel AG","u":"/media/press-releases/2017/enzymatica-ab-enzymatica-enters-into-partnership-agreement-with-stada-arzneimittel-ag/"},{"d":"2016-12-22","n":"ColdZyme demonstrates reduced sick leave during cold season","u":"/media/press-releases/2016/coldzyme-demonstrates-reduced-sick-leave-during-cold-season/"},{"d":"2016-12-21","n":"Enzymatica AB: Top-line results of new clinical trial","u":"/media/press-releases/2016/enzymatica-ab-top-line-results-of-new-clinical-trial/"},{"d":"2016-12-19","n":"Enzymatica AB: Bulletin from extraordinary general meeting in Enzymatica AB (publ)","u":"/media/press-releases/2016/enzymatica-ab-bulletin-from-extraordinary-general-meeting-in-enzymatica-ab-publ/"},{"d":"2016-12-01","n":"Enzymatica AB: NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING IN ENZYMATICA AB (publ)","u":"/media/press-releases/2016/enzymatica-ab-notice-of-extraordinary-shareholders-meeting-in-enzymatica-ab-publ/"},{"d":"2016-12-01","n":"Enzymatica AB: Extraordinary shareholders' meeting on changes to the board of directors","u":"/media/press-releases/2016/enzymatica-ab-extraordinary-shareholders-meeting-on-changes-to-the-board-of-directors/"},{"d":"2016-11-09","n":"Medical case report on promising treatment with ColdZyme® of patients with primary immunodeficiency","u":"/media/press-releases/2016/medical-case-report-on-promising-treatment-with-coldzyme-of-patients-with-primary-immunodeficiency/"},{"d":"2016-11-03","n":"Enzymatica AB: ColdZyme® sales continue to perform well","u":"/media/press-releases/2016/enzymatica-ab-coldzyme-sales-continue-to-perform-well/"},{"d":"2016-11-02","n":"Enzymatica AB: Enzymatica signs distribution agreement with Endeavour Consumer Health","u":"/media/press-releases/2016/enzymatica-ab-enzymatica-signs-distribution-agreement-with-endeavour-consumer-health/"},{"d":"2016-08-30","n":"Enzymatica AB: The board of directors in Enzymatica has resolved on a directed share issue of SEK 40.3 million","u":"/media/press-releases/2016/enzymatica-ab-the-board-of-directors-in-enzymatica-has-resolved-on-a-directed-share-issue-of-sek-403-million/"},{"d":"2016-07-18","n":"Enzymatica AB: Excellent volume growth for ColdZyme®","u":"/media/press-releases/2016/enzymatica-ab-excellent-volume-growth-for-coldzyme/"},{"d":"2016-05-25","n":"Bulletin from the Annual General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2016/bulletin-from-the-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2016-05-11","n":"Enzymatica's new rights issue completed - will be provided with SEK 60 million","u":"/media/press-releases/2016/enzymaticas-new-rights-issue-completed---will-be-provided-with-sek-60-million/"},{"d":"2016-05-03","n":"Enzymatica insiders plan to subscribe for SEK 16 million in new issue","u":"/media/press-releases/2016/enzymatica-insiders-plan-to-subscribe-for-sek-16-million-in-new-issue/"},{"d":"2016-04-27","n":"Customer studies: ColdZyme users fight colds early and actively","u":"/media/press-releases/2016/customer-studies-coldzyme-users-fight-colds-early-and-actively/"},{"d":"2016-04-26","n":"Notice of annual general meeting in Enzymatica AB (publ)","u":"/media/press-releases/2016/notice-of-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2016-04-20","n":"Enzymatica publishes prospectus","u":"/media/press-releases/2016/enzymatica-publishes-prospectus/"},{"d":"2016-04-20","n":"Information about Enzymatica’s new rights issue","u":"/media/press-releases/2016/information-about-enzymaticas-new-rights-issue/"},{"d":"2016-04-20","n":"Enzymatica - publication of the annual report 2015","u":"/media/press-releases/2016/enzymatica---publication-of-the-annual-report-2015/"},{"d":"2016-04-18","n":"Interim Report for Enzymatica AB (publ) January-March 2016","u":"/media/press-releases/2016/interim-report-for-enzymatica-ab-publ-january-march-2016/"},{"d":"2016-04-14","n":"Bulletin from the extraordinary shareholders' meeting in Enzymatica","u":"/media/press-releases/2016/bulletin-from-the-extraordinary-shareholders-meeting-in-enzymatica/"},{"d":"2016-04-01","n":"Enzymatica completes acquisition of Zymetech and includes new board members and representative to the nomination committee","u":"/media/press-releases/2016/enzymatica-completes-acquisition-of-zymetech-and-includes-new-board-members-and-representative-to-the-nomination-committee/"},{"d":"2016-03-24","n":"Acting CFO of Enzymatica appointed","u":"/media/press-releases/2016/acting-cfo-of-enzymatica-appointed/"},{"d":"2016-03-17","n":"Enzymatica AB: Updated time plan for the acquisition of Zymetech and the rights issue","u":"/media/press-releases/2016/enzymatica-ab-updated-time-plan-for-the-acquisition-of-zymetech-and-the-rights-issue/"},{"d":"2016-03-15","n":"Enzymatica announces new dates for its financial information","u":"/media/press-releases/2016/enzymatica-announces-new-dates-for-its-financial-information/"},{"d":"2016-03-15","n":"NOTICE OF EXTRAORDINARY SHAREHOLDERS MEETING IN ENZYMATICA AB (PUBL)","u":"/media/press-releases/2016/notice-of-extraordinary-shareholders-meeting-in-enzymatica-ab-publ/"},{"d":"2016-03-15","n":"The board of directors in Enzymatica has resolved on a rights issue of SEK 60 million","u":"/media/press-releases/2016/the-board-of-directors-in-enzymatica-has-resolved-on-a-rights-issue-of-sek-60-million/"},{"d":"2016-02-16","n":"Enzymatica AB: Strong growth in 2015 and acquisition for international expansion","u":"/media/press-releases/2016/enzymatica-ab-strong-growth-in-2015-and-acquisition-for-international-expansion/"},{"d":"2016-02-15","n":"Bulletin from the extraordinary shareholders' meeting in Enzymatica","u":"/media/press-releases/2016/bulletin-from-the-extraordinary-shareholders-meeting-in-enzymatica-2016-02-15/"},{"d":"2016-02-03","n":"Enzymatica moves forward its year-end report for 2015","u":"/media/press-releases/2016/enzymatica-moves-forward-its-year-end-report-for-2015/"},{"d":"2016-01-28","n":"NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING IN ENZYMATICA AB (PUBL)","u":"/media/press-releases/2016/notice-of-extraordinary-shareholders-meeting-in-enzymatica-ab-publ-2016-01-28/"},{"d":"2016-01-28","n":"Enzymatica signs acquisition agreement and prepares for international expansion with new share issue","u":"/media/press-releases/2016/enzymatica-signs-acquisition-agreement-and-prepares-for-international-expansion-with-new-share-issue/"},{"d":"2016-01-28","n":"Frequently asked questions and answers about Enzymatica's acquisition of Zymetech","u":"/media/press-releases/2016/frequently-asked-questions-and-answers-about-enzymaticas-acquisition-of-zymetech/"},{"d":"2016-01-27","n":"Questions and Answers – regarding the ASA decision, for marketing- and web material of ColdZyme in the UK","u":"/media/press-releases/2016/questions-and-answers--regarding-the-asa-decision-for-marketing--and-web-material-of-coldzyme-in-the-uk/"},{"d":"2015-11-12","n":"Enzymatica signs distribution agreement with Esteve in Spain","u":"/media/press-releases/2015/enzymatica-signs-distribution-agreement-with-esteve-in-spain/"},{"d":"2015-11-10","n":"Enzymatica signs distribution agreement with Tamro for the Finnish market","u":"/media/press-releases/2015/enzymatica-signs-distribution-agreement-with-tamro-for-the-finnish-market/"},{"d":"2015-10-16","n":"Enzymatica strengthens its presence in the UK through collaboration with the Lloyds pharmacy chain","u":"/media/press-releases/2015/enzymatica-strengthens-its-presence-in-the-uk-through-collaboration-with-the-lloyds-pharmacy-chain/"},{"d":"2014-11-17","n":"Fredrik Lindberg appointed CEO of Enzymatica","u":"/media/press-releases/2014/fredrik-lindberg-appointed-ceo-of-enzymatica/"},{"d":"2014-10-13","n":"Launch in Denmark expands ColdZyme® to all of Scandinavia","u":"/media/press-releases/2014/launch-in-denmark-expands-coldzyme-to-all-of-scandinavia/"},{"d":"2014-09-11","n":"New Chairman of the Board at Enzymatica","u":"/media/press-releases/2014/new-chairman-of-the-board-at-enzymatica/"},{"d":"2014-09-09","n":"Enzymatica appoints acting CEO","u":"/media/press-releases/2014/enzymatica-appoints-acting-ceo/"},{"d":"2014-07-24","n":"Enzymaticas veterinary products launched at the AVMA Annual Convention in Denver, USA","u":"/media/press-releases/2014/enzymaticas-veterinary-products-launched-at-the-avma-annual-convention-in-denver-usa/"},{"d":"2014-07-09","n":"Enzymatica: ColdZyme to be introduced in the UK","u":"/media/press-releases/2014/enzymatica-coldzyme-to-be-introduced-in-the-uk/"},{"d":"2014-06-11","n":"Enzymatica: ColdZyme to be introduced at pharmacies in Norway","u":"/media/press-releases/2014/enzymatica-coldzyme-to-be-introduced-at-pharmacies-in-norway/"},{"d":"2014-05-23","n":"Enzymatica presents COLDPREV study at scientific congress in Copenhagen","u":"/media/press-releases/2014/enzymatica-presents-coldprev-study-at-scientific-congress-in-copenhagen/"},{"d":"2014-05-19","n":"Bulletin from the Annual General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2014/bulletin-from-the-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2014-05-15","n":"Clarification: Shareholder proposals for the 2014 Annual General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2014/clarification-shareholder-proposals-for-the-2014-annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2014-05-05","n":"Enzymatica’s 2013 Annual Report now available","u":"/media/press-releases/2014/enzymaticas-2013-annual-report-now-available/"},{"d":"2014-04-25","n":"New date for Enzymaticas Interim Report January-March: May 19, 2014","u":"/media/press-releases/2014/new-date-for-enzymaticas-interim-report-january-march-may-19-2014/"},{"d":"2014-04-09","n":"Enzymaticas rights issue oversubscribed","u":"/media/press-releases/2014/enzymaticas-rights-issue-oversubscribed/"},{"d":"2014-02-12","n":"Enzymatica signs agreement for the sale of ColdZyme® at Swedish airports","u":"/media/press-releases/2014/enzymatica-signs-agreement-for-the-sale-of-coldzyme-at-swedish-airports/"},{"d":"2014-02-10","n":"Enzymatica announces launch plan for a proprietary mouthwash for gingivitis","u":"/media/press-releases/2014/enzymatica-announces-launch-plan-for-a-proprietary-mouthwash-for-gingivitis/"},{"d":"2014-02-03","n":"Enzymatica strengthens its organisation","u":"/media/press-releases/2014/enzymatica-strengthens-its-organisation/"},{"d":"2013-12-16","n":"Enzymatica increases turnover of 2013 – far beyond its financial goal","u":"/media/press-releases/2013/enzymatica-increases-turnover-of-2013--far-beyond-its-financial-goal/"},{"d":"2013-12-12","n":"Enzymatica expands its own Scandinavian operation and moves internationally with partners","u":"/media/press-releases/2013/enzymatica-expands-its-own-scandinavian-operation-and-moves-internationally-with-partners/"},{"d":"2013-12-02","n":"Enzymatica gets full market coverage through wholesale agreement with Tamro","u":"/media/press-releases/2013/enzymatica-gets-full-market-coverage-through-wholesale-agreement-with-tamro/"},{"d":"2013-11-06","n":"Enzymatica to offer new product line and sets up a subsidiary in the USA","u":"/media/press-releases/2013/enzymatica-to-offer-new-product-line-and-sets-up-a-subsidiary-in-the-usa/"},{"d":"2013-10-02","n":"Enzymatica: ColdZyme® Mouth Spray on pharmacy chain Medstop’s shelves","u":"/media/press-releases/2013/enzymatica-coldzyme-mouth-spray-on-pharmacy-chain-medstops-shelves/"},{"d":"2013-09-10","n":"Enzymatica conducts a directed issue totalling SEK 19 million","u":"/media/press-releases/2013/enzymatica-conducts-a-directed-issue-totalling-sek-19-million/"},{"d":"2013-09-09","n":"The COLDPREV study: ColdZyme Mouth Spray reduces both the viral load and the number of sick days with common cold in infected individuals, compared with placebo","u":"/media/press-releases/2013/the-coldprev-study-coldzyme-mouth-spray-reduces-both-the-viral-load-and-the-number-of-sick-days-with-common-cold-in-infected-individuals-compared-with-placebo/"},{"d":"2013-08-14","n":"Broad launch for ColdZyme® Mouth Spray, soon on Apoteket AB’s shelves","u":"/media/press-releases/2013/broad-launch-for-coldzyme-mouth-spray-soon-on-apoteket-abs-shelves/"},{"d":"2013-05-31","n":"Enzymatica signs agreement with Actavis for ColdZyme in the Nordic region","u":"/media/press-releases/2013/enzymatica-signs-agreement-with-actavis-for-coldzyme-in-the-nordic-region/"},{"d":"2013-05-06","n":"Annual General Meeting in Enzymatica AB (publ)","u":"/media/press-releases/2013/annual-general-meeting-in-enzymatica-ab-publ/"},{"d":"2013-04-10","n":"Enzymatica starts the process for listing on the Stockholm Stock Exchange","u":"/media/press-releases/2013/enzymatica-starts-the-process-for-listing-on-the-stockholm-stock-exchange/"},{"d":"2013-04-05","n":"Anders Jungbeck proposed as new member of the Board of Enzymatica","u":"/media/press-releases/2013/anders-jungbeck-proposed-as-new-member-of-the-board-of-enzymatica/"},{"d":"2013-03-21","n":"Christian W. Jansson is proposed as the new Chairman of the Board of Enzymatica","u":"/media/press-releases/2013/christian-w-jansson-is-proposed-as-the-new-chairman-of-the-board-of-enzymatica/"},{"d":"2013-03-21","n":"New date for Enzymatica’s Annual General Meeting","u":"/media/press-releases/2013/new-date-for-enzymaticas-annual-general-meeting/"},{"d":"2013-01-17","n":"Enzymatica to commence clinical market-monitoring study for the prevention and shortening of upper airway infection","u":"/media/press-releases/2013/enzymatica-to-commence-clinical-market-monitoring-study-for-the-prevention-and-shortening-of-upper-airway-infection/"},{"d":"2013-01-15","n":"Enzymatica: ColdZyme® Mouth Spray – for treating the common cold – to be introduced by the Swedish Apotek Hjärtat pharmacy chain","u":"/media/press-releases/2013/enzymatica-coldzyme-mouth-spray--for-treating-the-common-cold--to-be-introduced-by-the-swedish-apotek-hjartat-pharmacy-chain/"},{"d":"2012-12-21","n":"Enzymatica published in the international journal Infectious Diseases & Therapy – promising method for the prevention of colds using ColdZyme Mouth Spray","u":"/media/press-releases/2012/enzymatica-published-in-the-international-journal-infectious-diseases--therapy--promising-method-for-the-prevention-of-colds-using-coldzyme-mouth-spray/"},{"d":"2012-12-19","n":"Enzymatica signs agreement with the Kronans Droghandel pharmacy chain","u":"/media/press-releases/2012/enzymatica-signs-agreement-with-the-kronans-droghandel-pharmacy-chain/"},{"d":"2012-10-11","n":"Enzymatica announces Fredrik Håkansson as its new CFO","u":"/media/press-releases/2012/enzymatica-announces-fredrik-hakansson-as-its-new-cfo/"},{"d":"2012-10-02","n":"Mats Clarsund new EVP Research & Development at Enzymatica","u":"/media/press-releases/2012/mats-clarsund-new-evp-research--development-at-enzymatica/"},{"d":"2012-09-19","n":"Enzymatica inaugurates Scientific Advisory Board","u":"/media/press-releases/2012/enzymatica-inaugurates-scientific-advisory-board/"},{"d":"2012-08-13","n":"Enzymatica’s ColdZyme® Mouth Spray against common cold is registered with the Swedish Medical Product Agency","u":"/media/press-releases/2012/enzymaticas-coldzyme-mouth-spray-against-common-cold-is-registered-with-the-swedish-medical-product-agency/"}]



Trades

Price Volume Buyer Seller Time

Performance

Symbol ENZY
Currency SEK
Market Place FNSE
Latest Price  
Latest Change
Year High  
Year Low  
Number of Shares  

Share capital

On September 30, 2022, the share capital of Enzymatica AB was SEK 6,570,275.97 SEK, distributed among 164,256,840 shares, each with a par value of SEK 0.04.

The Company has only one class of stock. Each share entitles the holder to one vote at Enzymatica’s general meeting of shareholders. Each shareholder who is entitled to vote may vote at the general meeting for the full number of shares that he or she owns and represents. Each share carries equal rights to a part of the Company’s assets and profit.

Dividend

The Board of Directors does not intend to propose any dividend until the Company generates a profit and a positive cash flow.

Ownership structure

 NameNumber of shares Percentage of capital and votes (%) 
Mats Andersson, privately and through Abanico Invest AB36,398,19522.16%
Håkan Roos, through Roosgruppen AB22,284,62013.57%
Björn Algkvist through Fibonacci Asset Management & Fibonacci Growth Capital19,003,26111.57%
Gudmundur Palmason, through Fortus hf company7,142,4934.35 %
Ágústa Gudmundsdottir5,190,6793.16%
Nordnet Pensionsförsäkring AB4,972,0283.03%
Aktiebolaget Possessor4,180,0002.54%
Avanza Pension Försäkring AB3,236,2091.97 %
Bengt Baron, privately and through 5653 Sweden AB2,958,0271.80%
Swedbank Försäkring2,816,1481.71%
Holdings 10 largest shareholders108,181,66065.86%
Other56,075,10834.14 %
Total164,256,840100.0%

Euroclear 30 september 2022

Analyses

During the year Enzymatica was analyzed by ABG Sundal Collier and Erik Penser Bank.

ABG Sundal Collier
Rickard Anderkrans
rickard.anderkrans@abgsc.se

Erik Penser Bank
Johan Löchen
johan.lochen@penser.se